• by bcarlson@marketresearch.com
  • October 8 2014
  • vaccine


UK Tackles Flu With Children Before It Reaches Adults

UK Tackles Flu With Children Before It Reaches Adults

Two- to four-year-olds in the UK are for the second time being offered an egg-based nasal vaccine, and the UK will expand to older children.    The intention is to prevent influenza (flu) in hopes of not just protecting children from getting flu, but also of stopping the disease spreading from them to their family, caregivers and the wider population.  As we’ve indicated in our report on Biopharmaceutical and Vaccine production, http://www.kaloramainformation.com/Biopharmaceutical-Vaccine-Production-8357580/ government support drives vaccine production demand.

Last winter in the UK, over 900 people were admitted to intensive care with flu and 98 of them died, therefore the desire to stop the spread of flu to pregnant women, young children, those over 65 and those with conditions such as asthma and diabetes. The free vaccination for those aged two, three and four is now available, given as a nasal spray rather than an injection. This experimental vaccine distribution in the United Kingdom and other similar developments point to a growing flu vaccine market, as well as a growing market for the production of these vaccines. 

Three different production technologies are used to produce influenza vaccine: egg-based, cell-based and recombinant. The egg-based manufacturing process used to make both live attenuated (weakened) vaccine (the form of vaccine delivered nasally) and inactivated (killed) vaccine (the “flu shot”) has been in existence for more than 70 years. However, changes are coming to the field. Companies such as Novartis and Synthetic Genomics Vaccines are collaborating to apply synthetic genomics technologies to speed the production of the influenza seed strains - the starter cultures of a virus - required for vaccine manufacturing. This technology could reduce the vaccine production time by up to two months, which is critical in the event of a pandemic.

Manufacturers are looking for more efficient ways to produce vaccines as vaccination efforts such as the one in the UK drive the need for greater vaccine production. Kalorama discusses vaccine production technologies in its report, Biopharmaceutical and Vaccine Production Markets. The report also notes the current competitive environment, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity.

 

Information on Biopharmaceutical and Vaccine Production Markets can be found at KI: http://www.kaloramainformation.com/Biopharmaceutical-Vaccine-Production-8357580/.